In this manufacturing focussed newsletter, we are pleased to provide updates on the progress being made at the CGT Catapult manufacturing centre in Stevenage.
We have recently announced the fifth company to be collaborating at the centre to develop their manufacturing processes. TCR2 Therapeutics are the first US company to choose Stevenage as its global base for manufacture of next-generation novel T-cell receptor therapies.
Autolus has also become the first of the centre collaborators to be granted a manufacturing licence variation, allowing them to manufacture products for clinical trial at the centre.
Construction is continuing to progress to expand the centre, with the construction of six additional modules in the space on the second floor of the building. Construction is supported by £3.36m funding from the European Regional Development Fund (ERDF) and a £12m Industrial Strategy Challenge Fund (ISCF) award.
